Program
alirocumab
Also written as “Alirocumab”, “alirocumab SAR236553 (REGN727)” and “Alirocumab SAR236553 (REGN727)”.
Its studies are mostly in Hypercholesterolemia · Hyperlipoproteinemia Type II · Coronary Artery Disease · Homozygous Familial Hypercholesterolemia · Atherosclerosis, led by 3 companies.
Drug pageAlirocumab: every studyAll 78 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Sanofiits history only | 300 open or running | phase 4since Dec 24, 2015 | Feb 1, 2011 | none ahead |
| Regeneron Pharmaceuticalsits history only | 161 open or running | phase 4since Oct 28, 2016 | Nov 20, 2009 | Dec 29, 2026phase 2 · NCT07477704 |
| Kobe University | 20 open or running | phase 4since May 7, 2018 | May 7, 2018 | none ahead |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Kobe University only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- May 7, 2018First studies: 2 phase 4 studies in Coronary Artery DiseaseFirst studyNCT03552432, NCT03529253
TargetBeta
“A human immunoglobulin G1 (IgG1) monoclonal antibody directed against human proprotein convertase subtilisin/kexin type 9 (PCSK9), that can be used in the treatment of hypercholesterolemia”NCIt, by rule
“Subtilisin/kexin type 9 inhibitor”ChEMBL 37, by rule
Other programs on PCSK9
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| evolocumabrule | Amgen | phase 4 | 45 |
| inclisiranrule | Novartis | phase 4 | 37 |
| lerodalcibeprule | lib-therapeutics-llc | phase 3 | 14 |
| tafolecimabrule | Innovent Biologics | phase 3 | 8 |
| recaticimabrule | Jiangsu HengRui Medicine | phase 3 | 7 |
| QLC7401rule | Qilu Pharmaceutical | phase 3 | 5 |
| SYH2053rule | CSPC Pharmaceutical Group | phase 3 | 5 |
| SAL003rule | Shenzhen Salubris Pharmaceuticals | phase 3 | 3 |
| VERVE-102 | Eli Lilly | phase 2 | 2 |
| DNV001rule | hangzhou-dinovate-biotech-co-ltd | phase 2 | 1 |
| RBD7022rule | Qilu Pharmaceutical | phase 1 | 2 |
Studies
All 2 Kobe University leads, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT03552432Coronary Artery Disease · Japan | 4 | UNKNOWN | Sep 30, 2020 | 24 |
| NCT03529253Coronary Artery Disease · Japan | 4 | UNKNOWN | Sep 30, 2020 | 30 |
How it is read
Names in the registry
- “Alirocumab”, 28 entries
- “alirocumab SAR236553 (REGN727)”, 8 entries
- “Alirocumab SAR236553 (REGN727)”, 2 entries
- “alirocumab”, 2 entries
- “REGN727”, 2 entries
Conditions, from the studies’ own filings
- Hypercholesterolemia, 39 studies
- Hyperlipoproteinemia Type II, 2 studies
- Coronary Artery Disease, 2 studies
- Homozygous Familial Hypercholesterolemia, 1 study
- Atherosclerosis, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.